p53 gene mutations and p21 protein expression induced independently of p53, by TGF-β and γ-rays in squamous cell carcinoma cells

European Journal of Cancer

Volumn 35, Issue 2, 1999, Pages 278-283

  Yoneda, K ^a   Yokoyama, T ^a   Yamamoto, T ^a   Hatabe, T ^a   Osaki, T ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

rays; Apoptosis; Differentiation; p21; p53; Squamous cell carcinoma; TGF

Indexed keywords

PROTEIN P21; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; DNA DETERMINATION; DNA SEQUENCE; EXON; GAMMA RADIATION; GENE MUTATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; SQUAMOUS CELL CARCINOMA;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; GAMMA RAYS; GENES, P53; HUMANS; MUTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 0033083917     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00291-3     Document Type: Article

References (29)

1. Wang Y, Schwedes JF, Parks D, Mann K, Tegtmeyer P. Interaction of p53 with its consensus DNA-binding site. Mol Cell Biol 1995, 15, 2157-2165.
2. Funk WD, Pak DT, Karas RH, Wright WE, Shay JW. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol 1992, 12, 2866-2871.
3. Gottlieb TM, Oren M. p53 in growth control and neoplasia. Biochim Biophys Acta 1996, 1287, 77-102.
4. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997, 88, 323-331.
5. Skladanowski A, Larsen AK. Expression of wild-type p53 increases etoposide cytotoxicity in M1 myeloid leukemia cells by facilitated G2 to M transition: Implications for gene therapy. Cancer Res 1997, 57, 818-823.
6. El-Deiry WS, Tokino T, Waldman T, et al. Topological control of p21 WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 1995, 55, 2910-2919.
7. Slebos RJ, Lee MH, Plunkett BS, et al. p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc Natl Acad Sci USA 1994, 91, 5320-5324.
8. Kastan MB, Zhan Q, El-Deiry WS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992, 71, 587-597.
9. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995, 80, 293- 299.
10. Wang XW, Vermeulen W, Coursen JD, et al. The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev 1996, 10, 1219-1232.
11. Walker KK, Levine AJ. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Nad Acad Sci USA 1996, 93, 15335-15340.
12. Arrowsmith CH, Morin P. New insights into p53 function from structural studies. Oncogene 1996, 12, 1379-1385.
13. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75, 817-825.
14. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang X-F. Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA 1995, 92, 5545-5549.
15. Datto MB, Yu Y, Wang X-F. Functional analysis of the transforming growth factor β responsive elements in the WAF/Cip1/ p21 promoter. J Bid Chem 1995, 270, 28623-28628.
16. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994, 211, 90-98.
17. Li R, Waga S, Hannon GJ, Beach D, Stillman B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 1994, 371, 534-537.
18. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994, 369, 574-578.
19. Osaki T, Hirota J, Yoneda K, Yamamoto T, Ueta E. Distribution of surviving tumor cells after chemoradiotherapy in tongue and floor of mouth carcinoma. Head Neck 1994, 16, 218-226.
20. Sato M, Yoshida H, Kaji R, et al. Induction of bone formation in an adenoid cystic carcinoma of the maxillary sinus by adoptive immunotherapy involving intra-arterial injection of lymphokine-activated killer cells and recombinant interleukin-2 in combination with radiotherapy. J Biol Response Mod 1990, 9, 329-334.
21. Ueta E, Osaki T, Yamamoto T, Yoneda K. Induction of differentiation in maxillary adenoid cystic carcinomas by adoptive immunotherapy in combination with chemoradiotherapy. Oral Oncol 1998, 34, 105-111.
22. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 1994, 265, 346-355.
23. Nakai H, Kaneko H, Horiike S, et al. Multiple aberrant splicing of the p53 transcript without genomic mutations around exonintron junctions in a case of chronic myelogenous leukaemia in blast crisis: A possible novel mechanism of p53 inactivation. Br J Haematol 1994, 87, 839-842.
24. Zambetti GP, Levine AJ. A comparison of the biological activities of wild-type and mutant p53. FASEB J 1993, 7, 855-865.
25. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997, 387, 296-299.
26. Kubbutat MH, Jones SH, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997, 387, 299-303.
27. Xiao G, White D, Bargonetti J. p53 binds to a constitutively nucleosome free region of the mdm 2 gene. Oncogene 1998, 16, 1171-1181.
28. Ross J. mRNA stability in mammalian cells. Microbiol Rev 1995, 59, 423-450.
29. WAF/CIP1 expression in human breast carcinoma cells. Cancer Res 1996, 56, 5055-5062.